TAMPA, Fla., April 10, 2015 /PRNewswire/ -- Oxis International, Inc. (OXIS) (OXI.PA), a biotechnology company focused on cancer therapy development and commercialization, announced today that trading in its common stock will resume on Euronext Paris on April 14, 2015. Upon resumption of trading, the shares will trade in a double call auction trading mode (fixing) rather than the continuous trading mode formerly applicable to Oxis shares.

Anthony Cataldo, Oxis' CEO, said "We believe our new trading modality will enhance efficient trading across our markets on the OTC Bulletin Board and Euronext."  This modification has been approved by Euronext Paris.

ABOUT OXIS BIOTECH, INC. – OXIS is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the world's leading cannabinoid researchers and institutions to advance its technologies.

Contact
Jonathan Barkman
Riverview Capital Enterprises
1275 Glenlivet Dr Ste 100
Allentown, PA 18106
office  866-845-0105
fax     484-224-2999

Forward-Looking Statements – Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Mr. Cataldo's expression of belief that the Euronext trading mode will enhance trading efficiency is a forward-looking statement.  Factors which could cause actual results to differ materially from this forward-looking statement include such factors as new trading strategies unanticipated by the Company and the remaining potential for trading arbitrage between the OTC BB and Euronext markets despite the change in trading modality.  There is limited trading volume in the Company's shares which can contribute to volatility in the market price for such shares.  Other risks are detailed in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oxis-biotech-inc-announces-resumption-of-trading-of-common-stock-on-euronext-paris-300063942.html

SOURCE Oxis International, Inc.